Product Details Supplier Info More products

A consortium of experts involving Lorien Engineering Solutions has won a grant to develop a novel regenerative medicine product to help skin cancer patients.

Ektotherix, a bioresorbable scaffold material that assists patient tissue repair and regeneration, has been developed by York-based Neotherix supported by Lorien, as well as Smith and Nephew Advanced Wound Management.

Matrix Knowledge Group also joined the consortium to provide economic evaluation for the new product into clinical practice.

The consortium has secured 50 per cent funding for the GBP345,000 project from the Technology Strategy Board to take the therapy to the next stage of development.

The product works by applying a patch of Ektotherix following excision of the basal or squamous cell carcinoma by the clinician and this rapidly allows the wound space to be filled with (and then covered by) the patients’ own skin cells.

The product is formed via an electrospinning process and the highly porous three-dimensional scaffold structure supports the migration and proliferation of fibroblast cells from surrounding healthy skin tissue to facilitate healing of the wound.

This treatment provides an aesthetically acceptable repair to the skin, avoids the need to graft donor skin tissue from elsewhere on the patient or have an extended healing process with regular dressing changes with an increased risk of infection, and provides a cost-effective treatment for dermatologists and surgeons.

Neotherix’s initial clinical target concerns the post-surgical treatment of non-melanoma skin cancers.

Further clinical applications are expected.

Lorien Engineering Solutions is assisting in the development of the commercialisation pathway for the product.

In particular, Lorien is leading the definition of GMP manufacturing requirements and manufacturing risk evaluation, which will be required by regulatory authorities.

Lorien Engineering Solutions

View full profile